Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||malignant glioma||not applicable||AdV-tk + Valacyclovir||Phase II||Actionable||In a Phase II trial, addition of AdV-tk and Valacyclovir to standard of care improved meidan overall survival (17.1 vs 13.5 months) compared to standard of care alone in patients with malignant glioma (PMID: 26843484).||26843484|